GPH Stock Overview
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Galmed Pharmaceuticals Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.35 |
| 52 Week High | US$4.86 |
| 52 Week Low | US$0.26 |
| Beta | 0.87 |
| 1 Month Change | 18.12% |
| 3 Month Change | 8.64% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -91.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| GPH | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.7% | 2.2% | -1.0% |
| 1Y | n/a | -22.2% | 2.2% |
Return vs Industry: Insufficient data to determine how GPH performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how GPH performed against the German Market.
Price Volatility
| GPH volatility | |
|---|---|
| GPH Average Weekly Movement | 9.9% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: GPH has not had significant price volatility in the past 3 months.
Volatility Over Time: GPH's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 6 | Allen Baharaff | www.galmedpharma.com |
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.
Galmed Pharmaceuticals Ltd. Fundamentals Summary
| GPH fundamental statistics | |
|---|---|
| Market cap | €2.16m |
| Earnings (TTM) | -€6.42m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs GPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GPH income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$6.91m |
| Earnings | -US$6.91m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.15 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did GPH perform over the long term?
See historical performance and comparison